3TEFFERI A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2013, 88(6): 507-516.
4PALANDRI F, CATANI L, TESTONI N, et al. Long-term fol- low-up of 386 consecutive patients with essential thrombo- cythemia: safety of drug therapy[J]. Am J Hematol, 2009, 84(4): 215-220.
5MAMMERI H, GUILLON H, EB F, et al. Phenotypic and bio- chemical comparison of the carbapenem-hydrolyzing activities of five plasmid-bome ampC 13-1actamases [J]. Antimicrob Agents Chemother, 2010, 54(11): 4556-4560.
6GOTO M, SHIMIZU F, TAKEO N, et al. Drug-induced hyper- sensitivity syndrome due to carbapenem antibiotics[J]. J Dermatol, 2010, 37(4): 374-377.
7WANG X, ZHANG X, ZONG Z, et al. Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trialfJJ. Indian J Med Res, 2013, 138(6): 995-1002.
8LIN YF, YANG CH, SINDY H, et al. Severe cutaneous adverse reactions related to systemic antibiotics[J]. Clin Infect Dis, 2014, 58(10): 1377-1385.
9Hiraishi T, Miyata A,Hara T, et al. Bactericidal activity for biapenem against various bacteria[J]. JPN J Antibiot, 2001, 54(12) :581.
10Perry CM, Ibbotson T. Biapenem[J] . Drugs, 2002,62( 15 ) : 2 221 - 2 234.
